Lilly Wins Axid Patent Ruling; Ivax Directed To Pay Attorneys Fees

Ivax must pay Lilly's attorney fees after a court ruling found that its challenge of the Axid (nizatidine) chemical compound patent was not based on "reasonable and good faith" assumptions